148 related articles for article (PubMed ID: 22775439)
1. BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report.
Richtig E; Schrama D; Ugurel S; Fried I; Niederkorn A; Massone C; Becker JC
Br J Dermatol; 2013 Feb; 168(2):428-30. PubMed ID: 22775439
[No Abstract] [Full Text] [Related]
2. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
Schadendorf D
J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
[No Abstract] [Full Text] [Related]
3. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
4. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
5. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
[No Abstract] [Full Text] [Related]
6. Two cutaneous malignant melanomas at the same anatomic site: a case report with molecular evaluation.
Edinger JT; Radfar A; Jukic DM
J Cutan Pathol; 2009 Oct; 36 Suppl 1():74-9. PubMed ID: 19281486
[TBL] [Abstract][Full Text] [Related]
7. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1.
Skorokhod A; Capper D; von Deimling A; Enk A; Helmbold P
J Am Acad Dermatol; 2012 Sep; 67(3):488-91. PubMed ID: 22890732
[No Abstract] [Full Text] [Related]
8. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.
Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B
Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711
[TBL] [Abstract][Full Text] [Related]
9. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
10. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
11. BRAF inhibitors: research accelerates in wake of positive findings.
Brower V
J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
[No Abstract] [Full Text] [Related]
12. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma.
Blokx WA; Lesterhuis WJ; Andriessen MP; Verdijk MA; Punt CJ; Ligtenberg MJ
Am J Surg Pathol; 2007 Apr; 31(4):637-41. PubMed ID: 17414113
[TBL] [Abstract][Full Text] [Related]
14. Targeting metastatic melanoma.
Flaherty KT
Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
16. [BRAF mutation testing for the choice of melanoma treatment].
Imianitov EN
Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
[TBL] [Abstract][Full Text] [Related]
17. Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma.
Sebaratnam DF; Martin LK; Venugopal SS; Mangos G; Freiman J; de Souza P; Farnsworth A; Cheung K; Scolyer RA; Murrell DF
Int J Dermatol; 2014 Nov; 53(11):1409-11. PubMed ID: 25257244
[TBL] [Abstract][Full Text] [Related]
18. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
19. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma.
Ezra N; Hamid O; Behroozan D
Dermatol Surg; 2012 Jul; 38(7 Pt 1):1086-90. PubMed ID: 22563699
[No Abstract] [Full Text] [Related]
20. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
[No Abstract] [Full Text] [Related]
[Next] [New Search]